Bortezomib-Contained Chemotherapy and Thalidomide Combined With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) Play Promising Roles in Plasmablastic Lymphoma: A Case Report and Literature Review.
PMID: 25225082 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 19, 2014 Category: Cancer & Oncology Authors: Cao C, Liu T, Zhu H, Wang L, Kai S, Xiang B Tags: Clin Lymphoma Myeloma Leuk Source Type: research

A Longitudinal Computed Tomography Study of Lenalidomide and Bortezomib Treatment for Multiple Myeloma: Trabecular Microarchitecture and Biomechanics Assessed Using Multidetector Computed Tomography.
In this study, we investigated whether lenalidomide, similar to bortezomib, affects the microarchitecture and biomechanics of bones using clinical CT-based FEM. MATERIALS AND METHODS: Bone lesions were evaluated using whole-body 64-section multidetector CT scan. For microstructural- and CT/FEM analyses, the volume of interest was defined as a 10-mm thickness of the central part of the L3 vertebral body. Microstructural parameters and mechanical properties were calculated using a 3-D image analysis system. The changes from baseline to the second examination within groups were calculated. Relationships between baseline ...
Source: Clinical Lymphoma and Myeloma - August 12, 2014 Category: Cancer & Oncology Authors: Takasu M, Tani C, Kaichi Y, Sakoda Y, Kiguchi M, Date S, Kuroda Y, Sakai A, Awai K Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Melphalan/Total Body Irradiation-Conditioned Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients With Primary Plasma Cell Leukemia.
PMID: 25172535 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 2, 2014 Category: Cancer & Oncology Authors: Landsburg DJ, Vogl DT, Plastaras JP, Stadtmauer EA Tags: Clin Lymphoma Myeloma Leuk Source Type: research

R-CHOP or R-HyperCVAD With or Without Autologous Stem Cell Transplantation for Older Patients With Mantle Cell Lymphoma.
CONCLUSION: R-CHOP alone is less effective therapy for fit older patients with MCL. Intensifying therapy with R-HyperCVAD induction or ASCT consolidation after R-CHOP is associated with prolonged PFS and similar rates of toxicity. Consideration should be given to individual preferences regarding the differing method of administration and relative timing of toxicity with each regimen. PMID: 25174772 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2014 Category: Cancer & Oncology Authors: Frosch Z, Luskin MR, Landsburg DJ, Schuster SJ, Svoboda J, Loren AW, Porter DL, Stadtmauer EA, Nasta SD Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Review of Antibody-Based Immunotherapy in the Treatment of Non-Hodgkin Lymphoma and Patterns of Use.
Review of Antibody-Based Immunotherapy in the Treatment of Non-Hodgkin Lymphoma and Patterns of Use. Clin Lymphoma Myeloma Leuk. 2014 Aug 1; Authors: Cannon AC, Loberiza FR Abstract The creation of new cancer immunotherapies represents 1 of the most exciting advances taking place this decade. Although clinical studies continue to indicate improvement in clinical outcomes, the speed of its diffusion into actual practice is not known. It is important to understand practice variation in the use of recommended immunotherapies as new and more effective immunotherapies are developed. Additionally,...
Source: Clinical Lymphoma and Myeloma - August 1, 2014 Category: Cancer & Oncology Authors: Cannon AC, Loberiza FR Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Feasibility and Efficacy of Local Radiotherapy With Concurrent Novel Agents in Patients With Multiple Myeloma.
CONCLUSION: Treating MM with RT concurrently with CTx including NAs was safe and well tolerated in the majority of patients (14 of 16 [87.5%] for those taking NAs and 19 of 21 [90.5%] for all patients). Excellent clinical pain response (> 95%) was also seen in patients regardless if they were treated with RT + ST or RT alone. PMID: 25176474 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 1, 2014 Category: Cancer & Oncology Authors: Shin SM, Chouake RJ, Sanfilippo NJ, Rapp TB, Cook P, Formenti SC, Mazumder A, Silverman JS Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Clinicopathologic Analysis of POEMS Syndrome and Related Diseases.
CONCLUSION: Some unique clinicopathologic characteristics of POEMS syndrome can be used for differential diagnosis. This study provides increased awareness of POEMS syndrome. PMID: 25131854 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 23, 2014 Category: Cancer & Oncology Authors: Shi X, Hu S, Yu X, Zhuang Q, Luo M, Jiang Q, Wang L, Lu Y, Fei X, Xi X, Zhu Y Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia.
CONCLUSION: The development of t-MN in patients with MM is associated with poor outcomes. These patients, in general, have complex cytogenetic abnormalities and short complete remission and OS times. A better understanding of the disease biology and novel therapeutic approaches are warranted. PMID: 25107338 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 15, 2014 Category: Cancer & Oncology Authors: Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma).
Abstract Indolent nonfollicular B-cell lymphoma (INFBCL) has been classified in the World Health Organization 2008 system among the mature B-cell neoplasms and includes nodal and extranodal marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), and small lymphocytic lymphoma (SLL). Recently, the array and sequencing technologies have provided new insights into their molecular pathogenesis; the molecular discoveries, however, have not yet translated into consistent changes in their management. Thus, the therapy for INFBCL remains challenging. To promote widespread adoption of appropriate clinical practice,...
Source: Clinical Lymphoma and Myeloma - July 15, 2014 Category: Cancer & Oncology Authors: Tarella C, Arcaini L, Baldini L, Barosi G, Billio A, Marchetti M, Rambaldi A, Vitolo U, Zinzani PL, Tura S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Radiation Therapy Is an Effective Modality in the Treatment of Mantle Cell Lymphoma, Even in Heavily Pretreated Patients.
CONCLUSIONS: Our data add to accumulating evidence that mantle cell lymphoma is a radio-sensitive disease with excellent responses to relatively low radiation doses, even in patients with chemo-refractory disease. PMID: 25108680 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 15, 2014 Category: Cancer & Oncology Authors: Haque W, Voong KR, Shihadeh F, Arzu I, Pinnix C, Mazloom A, Medeiros LJ, Romaguera J, Rodriguez A, Wang M, Allen P, Dabaja B Tags: Clin Lymphoma Myeloma Leuk Source Type: research

[Incidence of haematological neoplasms in Castilla y Leon.]
CONCLUSIONS: A higher myeloid neoplasms incidence and lower lymphoid one than expected was observed. The turning point of incidence is between the 6th-7th decades of life, with a preference for male that decreases with age. There is an increased incidence of HNs in the area where a higher density of potentially polluting facilities is concentrated. PMID: 25015251 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 8, 2014 Category: Cancer & Oncology Authors: Rodríguez-García JA, Vázquez L, Ramos F, Cuevas B, Martín A, Smucler A, Guerola DN, Cantalapiedra A, Alonso JM, Fernández S, Díez E, Rodríguez MJ, Calmuntia MJ, Aguilar C, Sierra M, Gracia JA, Cebeira MJ, Cantalejo R, en nombre del Grupo de trabajo Tags: Med Clin (Barc) Source Type: research

Thrombosis and Hemostatic Abnormalities in Hematological Malignancies.
Abstract There is a paucity of data that pertain to thrombosis in patients with hematological malignancies. Recent studies showed that patients with lymphoma, multiple myeloma, and acute leukemia have an increased thrombotic risk, particularly at the time of diagnosis and during chemotherapy. We searched the PubMed database for articles on thromboembolic complications in patients with hematological malignancies published between 1996 and 2013. The incidence of thrombotic events is variable, and is influenced by the type and the stage of hematological malignancy, the antitumor therapy, and the use of central venous...
Source: Clinical Lymphoma and Myeloma - June 11, 2014 Category: Cancer & Oncology Authors: Colombo R, Gallipoli P, Castelli R Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Hepatic Extramedullary Disease in Multiple Myeloma With 17p Deletion.
PMID: 25018063 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 11, 2014 Category: Cancer & Oncology Authors: Ise M, Tsujimura H, Sakai C, Kumagai K Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Meta-Analysis of the Efficacy and Safety of Bortezomib Re-Treatment in Patients With Multiple Myeloma.
CONCLUSION: Based on these findings, bortezomib retreatment is well tolerated and appears efficacious in relapsed patients. In an era of new and emerging treatment options for relapsed and/or refractory myeloma, these data indicate that bortezomib retreatment might be a highly effective option in previously treated patients. PMID: 25023616 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 11, 2014 Category: Cancer & Oncology Authors: Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Extracavitary Primary Effusion Lymphoma Initially Presenting With Hemophagocytic Lymphohistocytosis.
PMID: 25027567 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 11, 2014 Category: Cancer & Oncology Authors: Shah NN, Harrison N, Stonecypher M, Frank D, Amorosa V, Svoboda J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Clinical Features of Patients With Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension.
CONCLUSION: PV and MF patients have a greater incidence of PHTN in our population, with thrombosis contributing to PHTN development in PV patients. Patients with splanchnic circulation thrombosis are potential candidates for screening for PHTN. These data might be useful for developing screening strategies for early detection of PHTN in patients with MPN. PMID: 25027569 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 11, 2014 Category: Cancer & Oncology Authors: Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, Yee K, Maganti M, Wong F, Gupta V Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E-Mutated Multiple Myeloma.
PMID: 24997557 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 11, 2014 Category: Cancer & Oncology Authors: Sharman JP, Chmielecki J, Morosini D, Palmer GA, Ross JS, Stephens PJ, Stafl J, Miller VA, Ali SM Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Perceived need for information of patients with haematological malignancies: a literature review.
CONCLUSION: Based on the limited number of data available, medical information is for patients of higher priority compared to psychosocial information. Patients need basic information on diagnosis, treatment, prognosis and all other topics. Need for detailed information varied between studies. Patients were satisfied with the provided information, preferably offered by doctors and nurses. RELEVANCE TO CLINICAL PRACTICE: The perceived need for information and satisfaction with the information provided differs strongly between patients. In clinical practice, more attention is needed for information tailored to the patie...
Source: Clinical Lymphoma and Myeloma - June 3, 2014 Category: Cancer & Oncology Authors: Rood JA, Eeltink CM, van Zuuren FJ, Verdonck-de Leeuw IM, Huijgens PC Tags: J Clin Nurs Source Type: research

The relationship between methylenetetrahydrofolate reductase polymorphism and hematological malignancy.
CONCLUSIONS: MTHFRC677T polymorphisms influence the risk of hematological malignancy among the population in Jiangsu province. Both MTHFR 677TT and MTHFR 1298CC genotypes increase susceptibility to myeloid leukemia. PMID: 24839819 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 24, 2014 Category: Cancer & Oncology Authors: Jiang N, Zhu X, Zhang H, Wang X, Zhou X, Gu J, Chen B, Ren J Tags: Clin Lab Source Type: research

Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.
Abstract Activation of the ER stress response is associated with malignant progression of B cell chronic lymphocytic leukemia (CLL). We developed a murine CLL model that lacks the ER stress-associated transcription factor XBP-1 in B cells and found that XBP-1 deficiency decelerates malignant progression of CLL-associated disease. XBP-1 deficiency resulted in acquisition of phenotypes that are disadvantageous for leukemic cell survival, including compromised BCR signaling capability and increased surface expression of sphingosine-1-phosphate receptor 1 (S1P1). Because XBP-1 expression requires the RNase activity of...
Source: Clinical Lymphoma and Myeloma - May 8, 2014 Category: Cancer & Oncology Authors: Tang CH, Ranatunga S, Kriss CL, Cubitt CL, Tao J, Pinilla-Ibarz JA, Del Valle JR, Hu CC Tags: J Clin Invest Source Type: research

Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies.
This study looked for differences in hematopoietic peripheral stem cells (HPSCs) mobilization in response to the three available G-CSFs, namely lenograstim, filgrastim, and pegfilgrastim. Between 2000 and 2012, 146 patients (66 M and 80 F) who underwent ASCT for multiple myeloma, non-Hodgkin's lymphoma or Hodgkin's lymphoma were studied. All patients received induction therapy and then a mobilization regimen with cyclophosphamide plus lenograstim, or filgrastim, or pegfilgrastim. From days 12 to 14, HPSCs were collected by two to three daily leukaphereses. Our results show that high-dose cyclophosphamide plus lenograstim a...
Source: Clinical Lymphoma and Myeloma - April 11, 2014 Category: Cancer & Oncology Authors: Ria R, Reale A, Melaccio A, Racanelli V, Dammacco F, Vacca A Tags: Clin Exp Med Source Type: research

Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
CONCLUSION: This study highlights the promise of a blood-based, sequencing minimal-residual-disease assay that can be used to measure MM disease burden at different time points and various disease stages. PMID: 24629890 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 22, 2014 Category: Cancer & Oncology Authors: Vij R, Mazumder A, Klinger M, O'Dea D, Paasch J, Martin T, Weng L, Park J, Fiala M, Faham M, Wolf J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Patterns of Relapse or Progression After Bortezomib-Based Salvage Therapy in Patients With Relapsed/Refractory Multiple Myeloma.
In this study, we retrospectively evaluated patterns of relapse or progression after bortezomib-based salvage therapy in patients with MM and analyzed prognostic significance according to patterns of relapse or progression. One hundred forty-eight patients were treated with bortezomib-based therapy between November 2004 and April 2012. Of these patients, 104 (70.3%) patients relapsed or progressed after bortezomib-based salvage therapy. We divided the patterns of relapse or progression to the 2 groups: (1) the isoform relapse or progression (group A) in 89 (85.6%) patients as disease findings at initiation of bortezom...
Source: Clinical Lymphoma and Myeloma - February 18, 2014 Category: Cancer & Oncology Authors: Ahn JS, Jung SH, Yang DH, Bae SY, Kim YK, Kim HJ, Lee JJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Small Lymphocytic Lymphoma Presenting As a Paraneoplastic Syndrome With Acute Central Nervous System Demyelination.
PMID: 24630921 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 18, 2014 Category: Cancer & Oncology Authors: Devito N, Mui K, Jassam Y, Taylor L, Pilichowska M, Cossor F Tags: Clin Lymphoma Myeloma Leuk Source Type: research

A Case of Mycosis Fungoides Transmitted From Donor to Recipient, and Review of Literature of T-Cell Malignancies After Transplantation.
PMID: 24637131 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 17, 2014 Category: Cancer & Oncology Authors: Loh JC, Cassarino DS, Grody WW, Chiu MW, Pinter-Brown LC Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Pernicious Anemia With Spuriously Normal Vitamin B12 Level Might Be Misdiagnosed As Myelodysplastic Syndrome.
PMID: 24630920 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 16, 2014 Category: Cancer & Oncology Authors: Shah DR, Daver N, Borthakur G, Hirsch-Ginsberg C, Oo TH Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Induction Bortezomib in AL Amyloidosis Followed By High Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Retrospective Study.
CONCLUSION: We observed that bortezomib-based induction is well tolerated in patients with and without cardiac involvement and suggest that this approach be studied in prospective multi-institutional trials. PMID: 24650974 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 16, 2014 Category: Cancer & Oncology Authors: Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT Tags: Clin Lymphoma Myeloma Leuk Source Type: research

The Choice of Multiple Myeloma Induction Therapy Affects the Frequency and Severity of Oral Mucositis After Melphalan-Based Autologous Stem Cell Transplantation.
We examined the effect of induction therapy before ASCT on ASCT mucositis rates. PATIENTS AND METHODS: Patients undergoing first 200 mg/m(2) HDM ASCT were assessed. Those receiving 
Source: Clinical Lymphoma and Myeloma - February 15, 2014 Category: Cancer & Oncology Authors: Fleming S, Harrison SJ, Blombery P, Joyce T, Stokes K, Seymour JF, Prince HM, Ritchie D Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma.
Abstract The phosphatidylinositol-3-kinase (PI3K) pathway is well known to regulate a wide variety of essential cellular functions, including glucose metabolism, translational regulation of protein synthesis, cell proliferation, apoptosis, and survival. Aberrations in the PI3K pathway are among the most frequently observed in cancer, and include amplifications, rearrangements, mutations, and loss of regulators. As a net result of these anomalies, the PI3K pathway is activated in many malignancies, including in Hodgkin and non-Hodgkin lymphomas, and yields a competitive growth and survival advantage, increased meta...
Source: Clinical Lymphoma and Myeloma - February 7, 2014 Category: Cancer & Oncology Authors: Westin JR Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient.
PMID: 24629851 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 4, 2014 Category: Cancer & Oncology Authors: Broccoli A, Pellegrini C, Celli M, Argnani L, Agostinelli C, Pileri S, Zinzani PL Tags: Clin Lymphoma Myeloma Leuk Source Type: research

What Determines Therapeutic Choices for Elderly Patients With DLBCL? Clinical Findings of a Multicenter Study in Portugal.
CONCLUSION: This was the first characterization of the clinical care of elderly Portuguese patients with DLBCL. We showed that R-CHOP is effective even in patients> 79 years, emphasizing that treatment decisions based on age alone can compromise treatment efficacy and outcome in fit patients. PMID: 24629852 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 4, 2014 Category: Cancer & Oncology Authors: Alvarez R, Esteves S, Chacim S, Carda J, Mota A, Guerreiro M, Barbosa I, Moita F, Teixeira A, Coutinho J, Príncipe F, Mariz JM, Silva MG Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Pralatrexate Alone or in Combination With Bexarotene: Long-Term Tolerability in Relapsed/Refractory Mycosis Fungoides.
CONCLUSION: Pralatrexate alone or in combination with low-dose oral bexarotene is well tolerated and capable of providing long-term responses in patients of advanced age with advanced-stage MF. PMID: 24589156 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 4, 2014 Category: Cancer & Oncology Authors: Talpur R, Thompson A, Gangar P, Duvic M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Posterior Reversible Encephalopathy Syndrome (PRES) Complicating Newly-Diagnosed Diffuse Large B-Cell Lymphoma.
PMID: 24581553 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 2, 2014 Category: Cancer & Oncology Authors: Sengupta S, Benkers T, Blitstein M, Palmer E, Plotkin SR, Abramson JS Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Extramedullary B Lymphoblastic Leukemia/Lymphoma (B-ALL/B-LBL): A Diagnostic Challenge.
PMID: 24589157 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 2, 2014 Category: Cancer & Oncology Authors: Geethakumari PR, Hoffmann MS, Pemmaraju N, Hu S, Jorgensen JL, O'Brien S, Daver N Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Overview of the international myeloma workshop 2013 kyoto.
PMID: 24461800 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 29, 2014 Category: Cancer & Oncology Authors: Shimizu K Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Treatment of smoldering myeloma: early or delayed?
PMID: 24461801 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 29, 2014 Category: Cancer & Oncology Authors: Fermand JP Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Bench work for targeted therapy to the microenvironment of myeloma bone disease.
PMID: 24461802 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 29, 2014 Category: Cancer & Oncology Authors: Abe M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Clinical Contribution of PET/CT in Myeloma: From the Perspective of a Radiologist.
PMID: 24461803 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 29, 2014 Category: Cancer & Oncology Authors: Nakamoto Y Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Vertebral Fracture Risk of Multiple Myeloma Assessed by a CT-based Finite Element and Trabecular Structure Analysis.
PMID: 24461804 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 29, 2014 Category: Cancer & Oncology Authors: Takasu M, Kaichi Y, Awai K, Asaoku H, Kuroda Y, Sakai A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Autologous stem cell transplantation for multiple myeloma in the era of novel agents.
PMID: 24461805 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 29, 2014 Category: Cancer & Oncology Authors: Shimazaki C Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Myeloma in Asia.
PMID: 24461806 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 29, 2014 Category: Cancer & Oncology Authors: Chou T Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Prevalence of monoclonal gammopathy of undetermined significance in Asia: a viewpoint from nagasaki atomic bomb survivors.
Abstract Exposure to ionizing radiation is a known environmental risk factor for a variety of cancers including hematological malignancies, such as leukemia, myelodysplastic syndromes, and multiple myeloma. Therefore, for Hiroshima and Nagasaki atomic bomb survivors (surviving victims who were exposed to ionizing radiation emitted from the nuclear weapons), several cancer-screening tests have been provided annually, with government support, to detect the early stage of malignancies. An M-protein screening test has been used to detect multiple myeloma at an early stage among atomic bomb survivors. In the screening ...
Source: Clinical Lymphoma and Myeloma - January 29, 2014 Category: Cancer & Oncology Authors: Iwanaga M, Tomonaga M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Autologous Stem Cell Transplantation for POEMS Syndrome.
PMID: 24461808 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 29, 2014 Category: Cancer & Oncology Authors: Nakaseko C Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Prognostic Implications of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype in Patients With Acute Myeloid Leukemia and Complex Cytogenetics.
CONCLUSION: Among patients with CK-AML, MK was associated with poor outcomes. Additional presence of C17 abns further worsens the outcome in these particularly poor-risk patients with AML. PMID: 24461514 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 21, 2014 Category: Cancer & Oncology Authors: Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Unfolded protein response inducers tunicamycin and dithiothreitol promote myeloma cell differentiation mediated by XBP-1.
Abstract The unfolded protein response (UPR) is an essential pathway for both normal and malignant plasma cells to maintain endoplasmic reticulum (ER) homeostasis in response to the large amount of immunoglobulin (Ig) output. The inositol-requiring enzyme 1-X-box binding protein-1 (IRE1-XBP-1) arm of the UPR pathway has been shown to play crucial roles not only in relieving the ER stress by up-regulating a series of genes favoring ER-associated protein degradation and protein folding, but in mediating terminal plasmacytic differentiation and maturation. Myeloma cells comprise various subsets arrested in diverse di...
Source: Clinical Lymphoma and Myeloma - December 20, 2013 Category: Cancer & Oncology Authors: Jiang H, Zou J, Zhang H, Fu W, Zeng T, Huang H, Zhou F, Hou J Tags: Clin Exp Med Source Type: research

Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase.
Abstract BACKGROUND: Accelerated phase CML most frequently represents a progression state in CML. However, some patients present with AP features at the time of diagnosis. There is limited information on the outcome of these patients who received TKIs as initial therapy. PATIENTS AND METHODS: We analyzed the outcome of 51 consecutive patients with CML who presented with features of AP at the time of diagnosis, including blasts ≥ 15% (n = 6), basophils ≥ 20% (n = 22), platelets 
Source: Clinical Lymphoma and Myeloma - December 9, 2013 Category: Cancer & Oncology Authors: Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Ruxolitinib for myelofibrosis-an update of its clinical effects.
Abstract Myelofibrosis (MF), a Philadelphia chromosome-negative myeloproliferative neoplasm, is characterized by progressive bone marrow fibrosis and ineffective hematopoiesis. Clinical hallmarks include splenomegaly, anemia, and debilitating symptoms. In 2 randomized phase III studies, the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib significantly improved splenomegaly and disease-related symptoms compared with placebo (Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment [COMFORT-I]) or best available therapy (COMFORT-II) in patients with intermediate-2 or high-risk MF. Although ruxolitinib therap...
Source: Clinical Lymphoma and Myeloma - November 20, 2013 Category: Cancer & Oncology Authors: Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Monoclonal gammopathy-associated proliferative glomerulonephritis.
Abstract Monoclonal gammopathy is characterized by circulating monoclonal immunoglobulin owing to clonal proliferation of immunoglobulin-producing B lymphocytes or plasma cells. Clonal proliferation of B lymphocytes is seen in B-cell lymphoma/leukemia, and clonal plasma cell proliferation is seen in multiple myeloma and monoclonal gammopathy of undetermined significance. The monoclonal immunoglobulin in the setting of a B-cell or plasma cell disorder can cause a proliferative glomerulonephritis via 2 mechanisms: (1) glomerular deposition of the monoclonal immunoglobulin with activation of the classical pathway of ...
Source: Clinical Lymphoma and Myeloma - November 1, 2013 Category: Cancer & Oncology Authors: Sethi S, Rajkumar SV Tags: Mayo Clin Proc Source Type: research

Autoimmune Neutropenia in Multiple Myeloma and the Role of Clonal T-Cell Expansion: Evidence of Cross-Talk Between B-Cell and T-Cell Lineages?
PMID: 24183500 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 29, 2013 Category: Cancer & Oncology Authors: Aryal MR, Bhatt VR, Tandra P, Krishnamurthy J, Yuan J, Greiner TC, Akhtari M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia.
ini M PMID: 24144836 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 19, 2013 Category: Cancer & Oncology Authors: Fontanelli G, Rocco M, Caracciolo F, Benedetti E, Buda G, Orciuolo E, Carulli G, Galimberti S, Azzarà A, Petrini M Tags: Clin Lymphoma Myeloma Leuk Source Type: research